Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.33 |
| ▸ | RGS12 | O14924 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286422 | 0.78 | NFKB1 (0.47) | — | |
| SCHEMBL3892270 | 0.66 | GABBR1 (0.48) | GABBR1RGS12CYP3A4TSHRGABRR1 | |
| SCHEMBL4588467 | 0.66 | GABBR1 (0.32) | GABBR1RGS12CYP3A4TSHRGABRR1 | |
| SCHEMBL31590201 | 0.60 | — | — | |
| SCHEMBL4589796 | 0.57 | — | — | |
| SCHEMBL4590569 | 0.53 | THRB (0.36) | — | |
| SCHEMBL31590156 | 0.51 | RGS12 (0.50) | GABBR1RGS12CYP3A4TSHRGABRR1 | |
| Phosphoric Acid SCHEMBL27960765 | 0.51 | MEN1 (0.55) | CYP3A4BLM | |
| SCHEMBL3900351 | 0.50 | GABBR1 (1.00) | GABBR1RGS12CYP3A4TSHRGABRR1 | |
| SCHEMBL3894225 | 0.50 | GABBR1 (1.00) | GABBR1RGS12CYP3A4TSHRGABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458669-A4 | NEUOROLOGICALLY-ACTIVE COMPOUNDS | UNIV SYDNEY (AU) | 2008-10-29 | — | — | EP | disclosed |
| US-6962907-B2 | Neurologically-active compounds | THE UNIVERSITY OF SYDNEY (AU) | 2005-11-08 | — | — | US | disclosed |
| US-20050004083-A1 | Neurologically-active compounds | NEURO THERAPEUTICS LIMITED (AU) | 2005-01-06 | — | — | US | disclosed |
| EP-1458669-A1 | NEUOROLOGICALLY-ACTIVE COMPOUNDS | THE UNIVERSITY OF SYDNEY (AU) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003045897-A1 | NEOROLOGICALLY-ACTIVE COMPOUNDS | UNIVERSITY OF SYDNEY (AU) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004083-A1 | Neurologically-active compounds | GABRA2, GABRA5, GABRE | GABBR1 17/4885RGS12 987/4885CYP3A4 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.